Altimmune Stock Forecast, Price & News

+0.01 (+0.11 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume516,390 shs
Average Volume1.19 million shs
Market Capitalization$348.29 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALT News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter.

Altimmune logo

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.23 out of 5 stars

Medical Sector

294th out of 2,220 stocks

Pharmaceutical Preparations Industry

142nd out of 869 stocks

Analyst Opinion: 4.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Altimmune (NASDAQ:ALT) Frequently Asked Questions

Is Altimmune a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Altimmune stock.
View analyst ratings for Altimmune
or view top-rated stocks.

What stocks does MarketBeat like better than Altimmune?

Wall Street analysts have given Altimmune a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Altimmune wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Altimmune's next earnings date?

Altimmune is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Altimmune

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) released its earnings results on Sunday, May, 16th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.01. The company earned $0.84 million during the quarter, compared to analyst estimates of $2.19 million. Altimmune had a negative net margin of 881.27% and a negative trailing twelve-month return on equity of 31.95%.
View Altimmune's earnings history

How has Altimmune's stock been impacted by COVID-19 (Coronavirus)?

Altimmune's stock was trading at $3.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALT stock has increased by 184.3% and is now trading at $9.07.
View which stocks have been most impacted by COVID-19

When did Altimmune's stock split? How did Altimmune's stock split work?

Shares of Altimmune reverse split before market open on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of Altimmune stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for ALT?

6 brokers have issued 1 year price targets for Altimmune's shares. Their forecasts range from $21.00 to $42.00. On average, they expect Altimmune's stock price to reach $28.17 in the next year. This suggests a possible upside of 210.5% from the stock's current price.
View analysts' price targets for Altimmune
or view top-rated stocks among Wall Street analysts.

Who are Altimmune's key executives?

Altimmune's management team includes the following people:
  • Dr. Vipin K. Garg, Pres, CEO & Director (Age 63, Pay $897.7k)
  • Mr. William Michael Brown, CFO & Principal Accounting Officer (Age 38, Pay $529.12k)
  • Dr. M. Scot Roberts, Chief Scientific Officer (Age 62, Pay $534.98k)
  • Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF, Chief Medical Officer (Age 68, Pay $577.19k)
  • Mr. Bertrand Georges Ph.D., Chief Technology Officer
  • Ms. Stacey Jurchison, Sr. Director of Investor Relations and Corp. Communications
  • Mr. José Ochoa, Chief Bus. Officer

Who are some of Altimmune's key competitors?

What other stocks do shareholders of Altimmune own?

What is Altimmune's stock symbol?

Altimmune trades on the NASDAQ under the ticker symbol "ALT."

Who are Altimmune's major shareholders?

Altimmune's stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.12%), Cutler Group LP (0.00%) and Patriot Financial Group Insurance Agency LLC (0.01%). Company insiders that own Altimmune stock include Klaus Schafer, Pharmaceutical Holdin Velocity, Philip Hodges, Venrock Healthcare Capital Par and Vipin K Garg.
View institutional ownership trends for Altimmune

Which major investors are selling Altimmune stock?

ALT stock was sold by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC. Company insiders that have sold Altimmune company stock in the last year include Klaus Schafer, and Philip Hodges.
View insider buying and selling activity for Altimmune
or view top insider-selling stocks.

Which major investors are buying Altimmune stock?

ALT stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and Cutler Group LP. Company insiders that have bought Altimmune stock in the last two years include Klaus Schafer, Venrock Healthcare Capital Par, and Vipin K Garg.
View insider buying and selling activity for Altimmune
or or view top insider-buying stocks.

How do I buy shares of Altimmune?

Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Altimmune's stock price today?

One share of ALT stock can currently be purchased for approximately $9.07.

How much money does Altimmune make?

Altimmune has a market capitalization of $348.29 million and generates $8.19 million in revenue each year. The company earns $-49,040,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

How many employees does Altimmune have?

Altimmune employs 43 workers across the globe.

What is Altimmune's official website?

The official website for Altimmune is

Where are Altimmune's headquarters?

Altimmune is headquartered at 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878.

How can I contact Altimmune?

Altimmune's mailing address is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. The company can be reached via phone at 240-654-1450 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.